Interleukin 27 attenuates collagen-induced arthritis

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and destruction.
• Interleukin 27 (IL-27) is a cytokine with complex roles in immune regulation.
• The specific role of IL-27 in RA pathogenesis and its therapeutic potential remain to be fully elucidated.

Purpose of the Study:

• To investigate the expression of IL-27 in the synovial membranes of RA patients.
• To evaluate the therapeutic efficacy of recombinant IL-27 in a murine model of collagen-induced arthritis (CIA).
• To assess the impact of IL-27 on T-cell responses in vitro and in vivo.

Main Methods:

• Immunohistochemistry and Western blot were used to detect IL-27 in RA synovial membranes.
• Mice with CIA were treated with IL-27 to assess disease progression and immunological changes.
• In vitro assays examined the effect of IL-27 on T-cell cytokine production (interferon-gamma and IL-17).

Main Results:

• IL-27 was detected in the synovial membranes of RA patients.
• IL-27 treatment significantly reduced disease severity, joint inflammation, synovial hyperplasia, and erosion in CIA mice.
• IL-27 administration decreased serum IL-6 and collagen-specific IgG2a levels.
• IL-27 treatment led to reduced production of interferon-gamma and IL-17 by immune cells from treated mice.

Conclusions:

• IL-27 is present in the joints of RA patients.
• Early administration of IL-27 demonstrates significant therapeutic potential for rheumatoid arthritis.
• IL-27 may serve as a novel therapeutic agent for RA, particularly when administered at the disease's onset.